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ABSTRACT
In disease-associated genes, the understanding of
thefunctionalsignificanceofdeepintronicnucleotide
variants may represent a difficult challenge. We have
previously reported a new disease-causing mechan-
ism that involves an intronic splicing processing ele-
ment(ISPE)inATM,composedofadjacentconsensus
50 and 30 splice sites. A GTAA deletion within ISPE
maintains potential adjacent splice sites, disrupts a
non-canonical U1 snRNP interaction and activates
an aberrant exon. In this paper, we demonstrate that
bindingofU1snRNAthroughcomplementaritywithin
a  40 nt window downstream of the ISPE prevents
aberrant splicing. By selective mutagenesis at the
adjacent consensus ISPE splice sites, we show that
thiseffectisnotduetoaresplicingprocessoccurring
attheISPE.FunctionalcomparisonoftheATMmouse
counterpart and evaluation of the pre-mRNA splicing
intermediates derived from affected cell lines and
hybrid minigene assays indicate that U1 snRNP bind-
ingattheISPEinterfereswiththecrypticacceptorsite.
Activation of this site results in a stringent 50–30 order
of intron sequence removal around the cryptic exon.
Artificial U1 snRNA loading by complementarity to
heterologous exonic sequences represents a poten-
tial therapeutic method to prevent the usage of an
aberrant CFTR cryptic exon. Our results suggest
that ISPE-like intronic elements binding U1 snRNPs
may regulate correct intron processing.
INTRODUCTION
Intronic sequences distant from the canonical splice sites are
mostly considered functionally neutral regarding pre-mRNA
splicing and are thus rarely considered when mapping splicing
regulatory elements and are not routinely sequenced in human
genetics screening. However, several examples have clearly
shown that ‘deep’ intronic mutations may affect the pre-
mRNA splicing process in a number of disease-associated
genes. The most frequent type of splicing mutation identiﬁed
in introns induces aberrant splicing by creating or strengthen-
ing splice sites (1–6). Because the splice-site consensus motifs
are degenerate, the introns contain many matches to each
consensus sequence, often with potential exon pairing,
which are never selected for splicing (7). In the presence of
a particular intronic context, mutations that create a new splice
site may deﬁne the boundary of the cryptic exon, which is then
included in the mature mRNA. For example, a disease-causing
intronic 19 C!T substitution (3849 + 10 kb T)  10 kb down-
stream of exon 19 of the CFTR gene has been reported to
create a perfect 50 splice site (50-ss) consensus. This activates
the inclusion of a 84 bp cryptic exon that contains a stop codon
(4). However, not all intronic mutations create or strengthen
splice sites, suggesting the existence of yet unknown splicing
regulatory elements (8,9).
Ataxia-telangiectasia is an autosomal recessive disorder
involving cerebellar degeneration, immunodeﬁciency, chro-
mosomalinstability, radiosensitivityandcancer predisposition
(10–12). Interestingly, a signiﬁcant proportion of mutations
in the affected ataxia-telangiectasia mutated (ATM) gene
( 48%) cause defects in splicing (13). We have previously
identiﬁed a new disease-causing mechanism that involves an
intronic splicing processing element (ISPE) in ATM intron 20
(9). The sequence of the ISPE (CAG/GTAAGT) resembles
adjacent consensus 50-ss and 30-ss, and is located in ATM
intron 20 approximately 1870 and 570 bp away from neigh-
boring exons 20 and 21, respectively. A 4 bp (GTAA) deletion
in the ISPE maintains these potential adjacent consensus 50-ss
and 30-ss, but the disruption of a non-canonical U1 snRNP
interaction with the ISPE activates an aberrant 65 bp exon.
Inclusion of this exon in mRNA is directly responsible for
ataxia-telangiectasiainanaffectedpatient. Theparticularityof
the ISPE mutation in intron 20 consists in the fact that it does
not affect splice sites that deﬁnes the boundary of the cryptic
exon. In fact, the deletion occurs 12 bp downstream and
53 bp upstream respectively from the two cryptic splice sites,
whose sequences were already present in the wild-type intron.
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doi:10.1093/nar/gki710We have previously shown that the activation of the cryptic
exon occurs through the disruption of a non-canonical inter-
action of U1 snRNP with the ISPE. Normally, U1 snRNP has a
well-known role in 50-ss deﬁnition (14), which does not seem
to apply in the case of the ISPE. This particular behavior led us
to suggest that this ISPE–U1 snRNP interaction could be
involved in resplicing, a mechanism originally identiﬁed in
the Drosophila gene Ubx and potentially involved in correct
intron processing (15,16). To gain greater insight into the
basic mechanism involved, we assessed the splicing effect
of U1 snRNP binding along the entire cryptic ATM exon,
the sequence-speciﬁcity of the adjacent consensus 50-ss and
30-ss of ISPE, and the pre-mRNA intermediates formed
in vivo. At the same time, we assessed the splicing role of
consensus ISPE sequences in mouse ATM introns and the
artiﬁcial recruitment of U1 snRNP on heterologous gene sys-
tems. Our results identify cis-acting sequences that can induce
aberrant splicing in the context of deep intronic mutations
that affect an ISPE sequence and provide a possible general
role of non-canonical U1 snRNP binding sites in correct intron
processing.
MATERIALS AND METHODS
Construction of hybrid minigenes
pATMD minigene has been previously described (9).
pATM12T, pATM13A and pATM GT2 were derived from
original pATM WT minigene (9) using PCR-mediated site-
directed mutagenesis. Genomic mouse DNA was ampliﬁed
with ATMmo1830dir, CATATGACGAGTAGGTAGGTTA-
GGATAG, and ATMmo2290rev, GCCAGCTTTATCCAC-
AAATCACTCACTT, primers that contain NdeI restriction
site at their 50 end. Ampliﬁed fragments were digested with
NdeI and cloned into the pTB NdeI( ) corresponding site
(17). pATMmD was generated by deletion of the GTAA in
mouse ISPE by PCR site-directed mutagenesis. Addition of
the 50-ss to generate pATMm50 and pATMmD50 was done by
cloning the annealed ATM m50ss dir, CATGGTAAGTAT,
and ATM m50ss rev, CATGATACTTAC, primers in the
unique NcoI site. To create pCF-C and pCF-T minigenes
corresponding to WT and 3849 + 10 kb C!T mutation (4),
respectively, human normal genomic DNA was ampliﬁed with
CFex19bdir, GGACTTAATCAAAATTCCTCATATGG, and
CFex19brev,ATCATATGCTGGTAATGCATGATATCTGA.
The ampliﬁed fragment of 824 bp that includes the cryptic
84 bp CFTR exon ﬂanked by 377 and 363 bp upstream and
downstream intronic sequences, respectively, was cloned in
the NdeI site of pTB Nde( ) (17). The 3849 + 10 kb C!T
mutation was created by PCR site-directed mutagenesis.
pFN-EDA minigene is a pBS derivative of pSVED-A Tot
(18) and contains the entire human ﬁbronectin EDA cassette
of 3096 bp (that include 92 and 109 bp of preceding and
following exonic sequences and the entire introns) cloned
in the BstEII site of the a-globin under the SV40 promoter
(19). We prepared a pcY7 a-tropomyosin minigene by cloning
the 630 bp T2F and T3R ampliﬁed fragment derived from
pY7 (20), which contains 138 bp of exon 2, 108 bp of
intron 2, and 150 bp of exon 3 in the KpnI and Xba sites
of pcDNA3. The sequence of the primers is as follows:
T2F, AGGGTACCAGCTTGTCGAGGAGGACATCTCAG
and T3R, CCTCTAGAGTCGATCGACCTGCAGG. To
create the pcY7ATM constructs, the EcoR1–BamHI 165 bp
long fragments derived from pATM (WT and D), which cor-
responds to the 65 bp cryptic exon ﬂanked by 52 and 44 bp
of intronic sequences, were cloned in the SmaI site of the
intron of pcY7 at a distance of 47 and 64 bp from the upstream
and downstream a-tropomyosin exons 2 and 3, respectively.
To prepare the pATM20 D, we ampliﬁed human DNA derived
from the affected patient with the following primers: ATM
J20 D, ATGGTGACCTAGAACCTACCAAATCCCTCCAC-
CTGCATATGTTATCTGGCCAGGTG,andATMBsteIIrev,
TAGGTCACCGTGGTTTCAGAAGTTCAAGAACATCTT-
CCATTGG.
The ATM-ampliﬁed fragment of 717 bp includes the ﬁrst
41 bp of exon 20 joined to the ATM D cryptic exon, the entire
downstream intron and 88 bp of exon 21. The PCR product
was digested with BsteII and cloned in the BstEII site of the
a-globin under the SV40 promoter (19). All minigene con-
structs were veriﬁed by DNA sequencing. To prepare different
U1snRNAs, the sequence between BclI and BglII of the
parental U1snRNA clone pG3U1(WT-U1), a derivative of
pHU1 (21), was replaced with mutated oligonucleotides as
previously described for the U1-D (9). The same strategy
was used to create U1-32, U1-40, U1-47, U1-66 and their
complementary sequences in the ATM cryptic exon are
shown in Figure 1B. The complementarity sequences of
U1-12T, U1-13A and U1-13A17A are shown in Figure 2A.
The tail of U1-CF19, U1-EDA8, U1-EDA19 and U1-a ex2
were created using the following oligonucleotides:
U1-CF19dir:GATCTCATTCATTACCTTGCAGGGGAGA-
TACCAT;
U1-CF19 rev: GATCATGGTATCTCCCCTGCAAGGTAA-
TGAATGA;
U1-EDA8 dir: GATCTCATTTAGGGCGATGCAGGGGAG-
ATACCAT;
U1-EDA8 rev: GATCATGGTATCTCCCCTGCATCGCCC-
TAAATGA;
U1-EDA19 dir: GATCTCATGCCAGTCCTGCAGGGGAG-
ATACCAT;
U1-EDA19 rev: GATCATGGTATCTCCCCTGCAGGACT-
GGCATGA;
U1-aGLO ex2 dir: GATCTCATTGGTGGTGGGGAAGGC-
AGGGGAGATACCAT;
U1-aGLO ex2 rev: GATCATGGTATCTCCCCTGCCTTC-
CCCACCACCAATGA.
Analysis of the hybrid minigene expression and
splicing precursors
The Hep3B (human hepatocarcinoma) cells were grown in
DMEM supplemented with 10% fetal calf serum. Plasmid
DNA were puriﬁed using Jetstar plasmid puriﬁcation system
by GENOMED. Cells were cotransfected with the DOTAP
reagent, with 1.5 mg of each minigene plasmid and when
necessary either with 0.5 mg of the control pCMV empty
vector, or with the indicated amounts of the U1snRNA codi-
fying plasmids per 35 mm dish of 60–75% conﬂuent cells in
the presence of commercial lipofectin. RNA was extracted
48 h later and cDNA was prepared using random primers
and reverse transcriptase as previously described (17). Trans-
fections with different pATMs, pCF and pEDA minigenes
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and visualized on 1.5–2% agarose gel stained with EtBr. The
same PCR conditions were applied for the other minigene
transfections using the following speciﬁc primers: pGLO
was ampliﬁed with E16DIR CGCACGCTGGCGAGTAT-
GGTGCGG and Glo 395Rev ACAGAAGCCAGGAACTTG-
TCCAG, pcY7ATMs were ampliﬁed with T2F and T3R to
detect the mature mRNA, pATM20D was ampliﬁed with a2-3
and ATM 2550rev CCAGGAAGCTCCTTTAAAAGCATT-
AGATA. The identity of the resulting splicing products was
veriﬁed by direct sequence analysis. in20F, GCTCAAGC-
TCTTAACTGCAACAG, and in20R rev, AATTCGGATCC-
CAGTACCACAGCCTT, primers were used in combination
with the appropriate oligonucleotides to identify the splicing
Figure 2. Analysis of mutants at the adjacent consensus 30-ss and 50-ss of human ISPE. (A) Nucleotide sequences of ATM intron 20 containing the point mutations
(boxed) that were created to disrupt adjacent consensus 30-ss or 50-ss at the ISPE at position 12 and 13, respectively and the double GT2 mutant. The cryptic exon is
showninuppercase,intronicsequencesareinlowercaseandthecrypticacceptor(ag)anddonor(gc)sitesareunderlined.Linesabovethesequenceshowtheposition
ofmodifiedU1snRNAsbindingsite.(B)Minigenesplicingassay.ThepATMminigenesweretrasfectedaloneorwiththeindicatedU1snRNAsinHep3Bcellsand
the resulting RT–PCR products analyzed on 1.5% agarose gel. The lower and higher MW bands correspond to normal intron processing and inclusion of the 65b p
cryptic exon, respectively. M is the molecular weight marker 1 kb.
Figure 1. Effect on pre-mRNA splicing of modified U1 snRNAs binding along the entire ATM D.( A) Schematic representation of ATM hybrid minigenes used in
transienttransfectionassay.Exonsareindicatedasblackboxes,intronsaslineanddottedlinesrepresentpossiblesplicingproducts.PrimersusedinRT–PCRanalysis
are shown as black arrows. The position where the ATM intron 20 sequences were cloned is indicated. (B) The upper panel shows the relevant portion of the
nucleotidesequencesoftheATMDintron20.Thecrypticexonisshowninuppercase,intronicsequencesareinlowercaseandthecrypticacceptor(ag)anddonor(gc)
sitesareunderlined.TheemptyunderlinedspaceinthesequencecorrespondingtotheGTAAdeletion.ThelinesabovethesequenceshowthepositionofmodifiedU1
snRNAsbinding site. Lower panel shows the resultof the splicingassay. pATM D minigenewas transfected in Hep3Bcells alone or with the indicated U1 snRNAs
andtheresultingRT–PCRproductsanalyzedon1.5%agarosegel.ThelowerandhigherMWbandscorrespondtonormalintronprocessingandinclusionofthe65bp
cryptic exon, respectively.
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ex19F,GACCGTGGAGAAGTAGAATCAATGG,andex22R,
GTAAGAAACTGTCCTTGAGCATCC, were used for amp-
liﬁcation experiments in lymphoblasts. Total RNA, extracted
from ATM heterozygous patient’s or normal lymphoblasts
with RNAwiz RNA isolation reagent, was treated with
DNAse RNAse-free and reverse-transcribed with random
primer as previously reported (9). The ampliﬁcation reaction
was performed for 40 cycles, 45 s at 94 C, 45 s at 54 C and
45 s at 72 C.
RESULTS
Position-dependent effect of U1 snRNPs binding on
the correct ATM intron pre-mRNA processing
Recruiting of U1 snRNA modiﬁed to be complementary to the
sequence created by the GTAA deletion in the ATM ISPE
induced normal pre-mRNA processing by inhibiting cryptic
exon inclusion (9). To gain insight into the U1 snRNP func-
tional interaction occurring along the entire cryptic exon, we
have now evaluated the effect of several modiﬁed U1 snRNAs
on the splicing pattern. To test the effect of the position of U1
snRNP association, we prepared snRNAs engineered to inter-
act with unique sequences at consecutive positions along the
cryptic ATM exon. Four different U1 snRNAs named U1-32,
U1-40, U1-47 and U1-66 were prepared, being complement-
ary to sequences between the GTAA deletion and the cryptic
50-ss (Figure 1B). These U1 snRNAs and the previously
described U1-D were cotransfected in Hep3B cells along
with the human D-ISPE minigene and the pattern of splicing
was analyzed by RT–PCR with speciﬁc primers (Figure 1). In
the ATMD minigene (with the GTAA ISPE deletion), the
cryptic exon was included in the processed mRNA and, as
previously described, cotransfection of U1-D restored normal
splicing (Figure 1B). Likewise, U1-32 and U1-40 restored
normal processing of the intron, whereas the other U1 snRNAs
designed to bind further downstream (U1-47 and U1-66) did
not affect the normal splicing pattern (Figure 1B). Control
experiments, in which the same U1 snRNAs were transfected
along with the WT minigene, did not show changes in the
splicing pattern (data not shown). These results indicate that
correct processing of ATM intron 20 requires binding of U1
snRNP in a sequence that spans between the ISPE and  40 nt
downstream. Binding of U1 RNAs near the cryptic 50-ss
(U1-47 and U1-66) had no effect. This position-dependent
effect indicates that, as previously suggested for normal
exons (22), binding of U1 snRNP inside the cryptic exon
mightproducestericinterferencebetweencomplexesinvolved
in the recognition of splicing signals, and in this case, the
acceptor splice site.
Sequence-specificity of adjacent consensus 30
and 50 splice site at the ISPE
Interestingly, even if U1 snRNP does not bind the ATM
sequence with the GTAA deletion (9), the adjacent CAG/
GTAAGT potential consensus 30-ss and 50-ss of the original
ISPE are not signiﬁcantly affected. In fact, the GTAA deletion
changes the sequence to CAG/GTGATA, which again main-
tains the ‘core’ consensus AG/GT. We have previously
suggested that these consensus splice sites could be potentially
used like resplicing signals or ‘zero exons’, as previously
found in Drosophila Ultrabithorax gene (15,16). When dis-
rupted, these sequences induce aberrant cryptic exon inclu-
sion. A 50-ss may be also deﬁned by U1 snRNP binding
downstream of the speciﬁc cleavage site (23). Thus, it seems
important to test if the position-dependent effect of U1 snRNP
bindingintheATM context alsorequiresthe presence ofintact
adjacent splice sites at the ISPE. To analyze the possible role
of ISPE acting as a resplicing signal, we prepared hybrid
minigenes (Figure 2A) where the putative resplicing site
AG/GT was destroyed by mutation at the 30-ss (at position
12 AT/GT) or at the adjacent 50-ss (at position 13 AG/AT)
(Figure 2A, pATM 12T and pATM 13A, respectively). We
also prepared a minigene in which two potential GT 50-ss were
inactivated to AT (Figure 2A, pATM GT2). Transfection of
these mutants induced aberrant splicing with inclusion of
the cryptic exon resembling the splicing pattern observed
with the original GTAA ISPE deletion found in the affected
patient (Figure 2B). To understand whether the selective dis-
ruption of the consensus adjacent splice site is sufﬁcient to
induce the aberrant splicing, we prepared additional U1
snRNAs variants, U1-12T, U1-13A and U1-13A17A. These
U1 snRNAs were designed to bind 12T, 13A and GT2 ISPE
mutants, respectively, through complementarity. Cotransfec-
tion of pATM 12T, pATM 13A and pATM GT2 with the
corresponding complementary U1 snRNAs showed the disap-
pearance of the cryptic exon (Figure 2). In addition, we tested
the effect of two additional U1 snRNA, U1-40 and U1-66 that
bound downstream and differentially affected the splicing pat-
tern in the ATM D construct (Figure 1). In the three minigenes,
cotransfection of U1-40 induces disappearance of the cryptic
exon, whereas U1-66 hasno effect (Figure2B). Cotransfection
experiments of wild-type ISPE minigene pATM WT with
different U1 snRNAs did not show any effect on the splicing
pattern (Figure 2B).
Altogether, these results indicate that binding of U1 snRNP
at a sequence located within 40 nt downstream of the ISPE
prevents aberrant splicing independent of sequence composi-
tionofitscore AG/GT adjacentconsensus50-ssand30-ss.Thus
the function of the ISPE is not dependent on the resplicing
signal but on a U1 snRNP complex located at the ISPE or
nearby.
Conservation of ISPE sequences in the mouse ATM
intron 20 require intronic cryptic splice sites to
induce aberrant splicing
To further evaluate the role of deep intronic elements in spli-
cing regulation, we compared human and mouse intron 20
sequences in the region of the ISPE. The mouse intron has
conserved ISPE and cryptic 30-ss, but no signiﬁcant homology
was observed for the peculiar human cryptic ‘GC’ 50-ss
(Figure 3A) suggesting that this difference may be important
in generating the aberrant splicing. To test this hypothesis, we
prepared four different mouse minigenes: wild-type mouse
ATM intron 20 (pATMm), the same construct with the
ISPE deletion (pATMmD), the mouse ATM with an artiﬁcial
50-ss (pATMm + 50-ss), and ﬁnally a minigene with the ISPE
deletion and the 50-ss (pATMmD+50-ss) (Figure 3B). Trans-
fection experiments showed that the wt mouse intron and the
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(Figure 3C). However, the deletion of the conserved mouse
ISPE activates the cryptic exon in the presence of an artiﬁcial
50-ss located in the corresponding position of the human ‘GC’
50-ss (Figure 3C). To studythe role ofISPEsas possibletargets
for disease-causing mutations, we also evaluated two similar
sequences in human introns 31 and 47 not ﬂanked by potential
cryptic splice sites. Analysisof the corresponding hybrid mini-
gene showed that the ISPE deletions did not affect the splicing
pattern (data not shown), strongly suggesting that aberrant
splicing due to disruption of a consensus ISPE depends on the
contextoftheintronicsequenceswheretheISPEislocatedand
in particular, on the presence of ﬂanking cryptic splice sites.
U1snRNP recruitment by sequence complementarity
to heterologous exonic sequences causes splicing
inhibition in some contexts
The splicing inhibitory effect of U1 snRNP was further invest-
igated on exonic pre-mRNA sequences. We have previously
shown that introduction of the ISPE element near the 30-ss of
CFTR exon9inducesexonskipping.Thesameeffect wasseen
by introducing deleted ISPE sequences and cotransfecting the
corresponding U1 snRNA (U1 D) (9). To evaluate a potential
useful tool to modulate exon-speciﬁc splicing and to correct
aberrant splicing, we now extended our observations by per-
forming complementation experiments with modiﬁed U1
snRNAs engineered to speciﬁcally bind at the 50 portion of
three exons: a pathological cryptic exon inclusion in CFTR,
the EDA ﬁbronectin exon and the second exon of a-globin.
The 3849 + 10 kb C!T mutation is known to create a donor
site in CFTR intron 19 leading to variable inclusion of a 84 bp
long cryptic exon containing a stop codon (24). The EDA exon
is a well-characterized example of an alternatively spliced
exon subject to tissue-speciﬁc and developmental regulation,
whereas the a-globin exon is constitutively included. These
model systems were selected due to their potentially different
exon deﬁnition properties. The minigenes corresponding to
the three gene systems were cotransfected with different U1
RNAs, each speciﬁcally designed to bind to the 50 portion of
the corresponding exon. In the CFTR case, recruitment of
modiﬁed U1 snRNA partially switched a cryptic exon into
the original processed intronic sequence (Figure 4, left panel).
Similar results were obtained for the ﬁbronectin exon where
two different U1 snRNAs designed to bind 8 and 19 nt down-
stream of the 30-ss induced EDA skipping (Figure 4, central
panel). On the contrary, binding of U1 at the constitutively
included a-globin exon did not modify the splicing patterns
(Figure 4, right panel).
Analysis of pre-mRNA splicing intermediates in vivo
and in hybrid minigenes
The function of the ISPE is presently not clear, it is possible
that the U1 snRNP complex formed in deep intronic sequences
may facilitate but may not be essential for efﬁcient removal of
the intron. To understand whether the ISPE deletion has a
preferential effect on the excision of upstream or downstream
intron sequences and thus potentially interferes with the 30-ss
or 50-ss, we studied the pre-mRNAs formed in vivo in lympho-
blast cell lines derived from normal and ATM-affected indi-
viduals. We performed in vivo analysis of pre-mRNAs by
Figure 3. Functionalcomparative analysis of the ISPEs in human and mouse ATMintron 20. (A) Alignmentof human (h)and mouse (m) ATM intron 20 sequences
revealsignificantconservationatthecryptic30 ssandattheISPE(boxed).ThemouseintrondidnotshowaconservedGCcryptic50-ss.Thehumancrypticsplicesites
are underlined and the human cryptic exon is in uppercase. (B) Nucleotide sequences of the mouse ATM hybrid minigenes. The conserved 30-ss and mouse ISPE
(mISPE)areboxed.InpATMm50 andpATMmD50,theadditionalsequencethatcontaintheconsensus50-ssisindicated.Underlinednucleotidesarethecrypticsplice
sitesusedinpATMmD50 construct.(C)SplicingassayofthemouseATMhybridminigenes.MouseATMminigenesweretransfectedinHep3Bcellsandthepattern
of splicing analyzed with specific primers. RT–PCR amplified fragments were resolved on a 2% agarose gel. The lower MW product correspond to normal intron
processing, the higher MW band found in pATMmD50 correspond to inclusion of the cryptic exon. M is the molecular weight marker 1 kb.
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ning exon 19 (ex19F) and the downstream portion of intron
20 (in20R) or the upstream segment of intron 20 (in20F)
and exon 22 (ex22F) (Figure 5A). In the affected cells,
ampliﬁcation with the ex19F and in20R primers revealed a
pre-mRNA form that corresponds to exon 19, exon 20, the
cryptic exon and retention of the downstream portion of intron
20(Figure 5A,lane 1), whereas analysiswithin20F and ex22R
Figure 5. AnalysisofATMpre-mRNAsplicingprecursorsinlymphoblastsandhybridminigenes.(A)Theleftpanelshowsaschematicrepresentationofthehuman
ATM gene and the location of the primers used for RT–PCR analysis. Exons are indicated as boxes, introns as line and dotted lines represent the possible splicing
products.ThecrypticATMexonisshownasagreyboxwithdottedoutline.TotalRNA,extractedfromATMpatient(ATMD)andnormallymphoblasts,wastreated
withDNAseRNAse-free,reversetranscribedandamplifiedwiththeindicatedprimers.Lanes1and3correspondtoamplificationwithex19Fandin20R,lanes2and4
to amplification with in20F and ex22R. The identity of the amplified precursor product detected in the affected lymphoblasts which contains exon 19, exon 20, the
ATMD cryptic exon and the downstream intron 20 sequences is schematically represented on the right on the splicing assay along the primers utilized. Control
experimentswithoutreverse transcriptase didnotrevealany amplifiedband(datanotshown).Mis the molecularweightmarker1 kb.(B) Schematic representation
oftheshorta-tropomyosinhybridminigene(pcY7ATM)usedintransienttransfectionassay.Tropomyosinexons2(T2)and3(T3)andtheATMcrypticexon(grey)
are boxed. The length of the intronic sequences (shown as lines and not in scale) flanking the ATM cryptic exon is of 99 and 108 bases, respectively. Dotted lines
represent the possible splicing products. pcY7ATM wt and D minigenes were transiently transfected in Hep3B cells and the pattern of splicing analyzed with the
indicatedprimers.Amplification experiments of maturemRNAwithT2Fand T3Ris shownon the right.As expectedthe GTAAdeletionactivatesthe crypticexon
also in the shortcontextof the a-tropomyosin gene.(C) Resultofamplificationexperiments of pcY7ATMwt and D withT2F-in20Rand in20F-T3Rprimerson the
leftandrightpanel,respectively.Thepre-mRNAformsareschematicallyrepresentedalongwiththeprimersutilized.Evenlanescorrespondtocontrolamplification
of RNA samples without reverse transcriptase. All amplified bands were verified by sequencing.
Figure 4. Effect of modified U1 snRNAs on splicing in heterologous exonic sequences. The upper panel shows a schematic representation of the three hybrid
minigenes that correspond to the 84 bp cryptic exon in CFTR (pCF), the 270 bp fibronectin alternatively spliced EDA exon (pFN-EDA) and the constitutively
included204bpexon2ofa-globin(pGLO).Exonsareindicatedasboxes,intronsassolidlineanddottedlinesrepresentthesplicingproducts.ThedotinpCFshows
the position of the CFTR intron 19 C!T mutation that creates a fully competent 50-ss. Above each exon are depicted the modified U1 snRNAs binding sites. The
lowerpanelshowstheresultsofthetransfectionexperiments.HybridminigenesweretransfectedaloneorwiththeindicatedU1snRNAsinHep3Bcells.TotalRNA
was amplified using primers specific for each construct. Resulting products were analyzed on 1.5% agarose gel. The exon inclusion (+) or exclusion ( ) forms are
indicated on the right of each splicing assay.
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normal cells with either ex19F-in20R or in20F-ex22R primers
did not show any ampliﬁed band (Figure 5A, lanes 3 and 4,
respectively).
To extend this observation, and to conﬁrm the absence of
ampliﬁed products with primers located in the upstream por-
tion of intron 20, we searched for the same intermediates in a
shorter intron version of the ATM hybrid minigene, which was
prepared to improve the RT–PCR detection of pre-mRNA
forms (Figure 5B). Control experiments with these minigenes
showed that, like the previously reported pTB ATM minigene
(9), the D ISPE mutation induced cryptic exon inclusion
(Figure 5B, right panel). To analyze the pre-mRNA forms
produced in the transfected cells, total RNA was ampliﬁed
with speciﬁc primer pairs that span intronic and exonic
sequences corresponding to T2F-in20R (Figure 5C, left panel)
or in20F-T3R (Figure 5C, right panel). Due to the reduced size
of the introns ﬂanking the cryptic exon, ampliﬁcation experi-
ments in WT and D ISPE minigenes showed the full-length
unprocessed transcripts with both pairs of primers (Figure 5C,
lanes 1, 3, 5 and 7). The partially spliced pre-mRNA form,
exclusively present in the D ISPE, corresponded to the exclu-
sion of the 30 portion of intron 20 that precedes the cryptic
exon (Figure 5C, lane 3) consistent with the in vivo observa-
tions (Figure 5A). To prove that this intermediate, once
formed, is processed to the ﬁnal mature mRNA in vivo in
the original context, we prepared the pATM20 D minigene
(Figure 6A). In this construct, the splicing intermediate lack-
ing the preceding intron is embedded in the natural context
with theﬂankingATM exon20,downstreamintronsequences,
and ATM exon 21. Transfection of pATM20D showed a pro-
cessed transcript similar to that found in vivo in the affected
cells, i.e. including the entire cryptic exon (Figure 6B). Alto-
gether, the data show that while in the wild-type situation no
intron precursors can be detected, in the ISPE deletion, accu-
mulation of precursors retaining the downstream intron can be
seen. Thus, it appears that deletion of the ISPE ﬁrst causes the
removal of the intron 20 sequence upstream of the cryptic
exon, followed by the removal of downstream sequences.
This process suggests that U1 snRNP binding at the ISPE
has a preferential inhibitory effect on the use of the cryptic
30-ss. The order of aberrant intron removal seems to proceed in
a strict 50–30 direction as implied by the fact that the 30 portion
of intron 20 is processed before the upstream portion in the
ISPE deletion, and the overall result is suggestive of an effect
of the ISPE in splicing efﬁciency.
DISCUSSION
A growing body of evidence indicates that genomic variations
at non-canonical splicing regulatory elements may unexpec-
tedly affect the splicing process (25,26). However, their
assessment as disease-causing mutations may be a difﬁcult
task as the nature of affected splicing regulatory elements
is largely unknown and direct RNA analysis is not routinely
performed in genomic screenings. We have previously repor-
ted a mutation in a deep intronic ISPE element in the ATM
gene, which is located far from coding sequences and differs
from the majority of the described intronic variants in that it is
not directly concerned with changes at splice sites. However,
the ISPE ‘CAG/GTAAGT’ sequence contains adjacent con-
sensus 30-ss and 50-ss that are never used. A GTAA deletion at
ISPE maintains potential adjacent splice sites, disrupts a non-
canonical U1 snRNP interaction, and activates an aberrant
exon (9). In this paper, we have carefully characterized the
composition of cis-acting sequences around the ISPE signal
and the role of non-canonical U1 snRNP binding.
To explore the mechanism by which the ISPE–U1 snRNP
complex in the ATM intron interferes with the cryptic splice
sites, we performed experiments with complementary U1
snRNAs on the ATM D minigene. These U1 snRNAs vary
in the 50 end sequence to bind at sequential positions along the
cryptic exon (Figure 1). The artiﬁcial recruitment of U1
snRNPs at the upstream portion of the cryptic exon induces
normal intron processing (U1-D, U1-32 and U1-40), whereas
further downstream recruitment (U1-47 and U1-66) has no
effect (Figure 1). This result identiﬁes a critical region of
 40 nt downstream the GTAA ISPE deletion in the ATM
D (or 50 nt downstream the cryptic 30-ss) where U1 snRNP
binding induces normal intron 20 processing. Interestingly, the
distance from the 30-ss adequately corresponds to the sugges-
ted minimum size of 50 nt required for internal exon inclusion
in vertebrates (22).
Comparison between wild-type and the GTAA deletion
mutants (CAG/GTAAGT versus CAG/GTGATA sequences,
respectively) shows that the adjacent consensus 30-ss and 50-ss
AG/GT are maintained. Since these adjacent consensus splice
sites might represent a re-splicing signal or ‘zero exon’ that
regulates and ensures appropriate intron processing (9,15,16),
we evaluated whether the core AG/GT sequence is required
for normal processing induced by U1 snRNAs. We created
site-directed mutants at either adjacent splice sites that were
analyzed alone or in the presence of complementary U1
snRNAs. The results shown in Figure 2 indicate that the
position-dependent effect of the U1 snRNA prevents aberrant
splicing independent of the sequence composition of its core
AG/GT adjacent 50 and 30 consensus splice sites. Thus, forma-
tion of the U1 snRNP complex in a critical position is sufﬁ-
cient to induce normal ATM intron processing. This effect
is independent of the putative resplicing signal contained in
the ISPE. On the other hand, ampliﬁcation experiments in
normal cells and in the corresponding hybrid minigene do
Figure 6. Thepre-mRNAidentifiedinvivoiscorrectlysplicedinthecontextof
the ATM minigene. The upper panel shows a schematic representation of the
pATM20 D minigene. ATM exon 20, 21 and the cryptic ATM exon with the
GTAA deletion (D and grey) are boxed. Dotted lines represent the splicing
products and the double arrow at the 50 end the SV40 promoter. The minigene
was transfected in Heb3B cells and the pattern of splicing analyzed with a2-3
and ATM 2550rev primers. The identity of the processed band is shown. M is
the molecular weight marker 1 kb.
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AG/GT signal (Figure 5). Even if this evidence seems to
exclude that the U1 snRNP complex formed on deep ISPE
participates in resplicing, the precursors originating from the
usage of the resplicing signal might be rapidly processed to the
mature mRNA and are not detected in the ampliﬁcation assay.
Additional experiments are necessary to carefully study the
kinetics of the splicing reaction of introns containing intronic
ISPE–U1 snRNP complexes.
To test the importance of cryptic splice sites around the
ISPE, we functionally compared the splicing requirement in
the mouse ATM intron 20 sequences. In order to induce aber-
rant splicing, deletion of the mouse-conserved ISPE requires
at least the presence of cryptic splice sites that deﬁne the
boundaries of the exon (Figure 3) suggesting that additional
cis-acting elements adjacent to the ISPE are involved. Actu-
ally, deletion of other intronic human ATM ISPE consensus
sequences not ﬂanked by cryptic splice sites did not result in
aberrant splicing, i.e. activation of a cryptic exon (data not
shown).
To analyze the interference with the cryptic splice sites
more in detail, we identiﬁed the pre-mRNA splicing precurs-
ors derived from lymphoblast cells and from hybrid minigene
experiments. The ISPE deletion and the resulting disruption of
U1 snRNP binding induces the unique formation of a splicing
precursor that contains the downstream but not the upstream
intron, stimulating a stringent 50!30 order of intron removal
around the cryptic exon (Figure 5). This obligatory splicing
direction induced by the deletion can be observed even in
hybrid minigenes with a short intronic context (Figure 5C)
and the precursor is properly spliced in vivo in the natural
context that includes the ﬂanking ATM exons and natural
splice sites (Figure 6). This preferential effect on the excision
of the upstream intron suggests that one mechanism of activa-
tion of the ATM cryptic exon is an interference of the ISPE–
U1 snRNP complex with the cryptic 30-ss.
We have previously shown that transferring an ISPE
sequence into an exon induces its skipping and that this effect
is mediated by U1 snRNP (9). We now extended this obser-
vation by evaluating the artiﬁcial recruitment of U1 snRNAs
by complementarity in other heterologous gene systems. We
observed that splicing inhibition occurred in the case of the
ﬁbronectin EDA alternative splicing and in the 3849 + 10 kb
C!T CFTR mutation, but not for the constitutively included
a-globin minigene (Figure 4), suggesting that exon-speciﬁc
elements determine the inhibitory role of U1 snRNP. It is
possible that the weaker exon deﬁnition present in the altern-
ative spliced EDA and CF cryptic mutation, as compared with
the constitutive globin exon, mediates the splicing inhibitory
effect of the U1 snRNAs. This reduction in exon deﬁnition
may not be simply due to weak splice sites, but result from
more complex exon-speciﬁc interactions that involve both
exonic and intronic regulatory elements whose function
strongly depend on the context of individual exons. In fact,
exonic splicing enhancers have been identiﬁed not only in
alternatively spliced exons, but also in constitutive globin
exons (27). In addition, this result indicates that previously
reported exonic splicing silencers identical to ISPE (28) may
exert their inhibitory effect through non-canonical binding to
U1 snRNP. Interestingly, the increase in the level of correctly
spliced RNA transcribed from an endogenous CFTR allele
carrying the 3849 + 10 kb T mutation may have therapeutic
potential. The speciﬁcity provided by the complementarity of
the U1 snRNA or by antisense oligoribonucleotides (29) is a
preferable therapeutic strategy to correct this splicing defect
when compared to overexpression of regulatory splicing fac-
tors like SC35 and Htra2-b (30), which have widespread
splicing effects in the cell (31,32).
ISPE–U1 snRNP complexes, independent of their interfer-
ence with cryptic splice sites, could facilitate ATM intron
splicing. U1 snRNA has been suggested to regulate transcrip-
tion initiation by binding to the transcription factor TFIIH
(33), and U1 snRNP interaction in the ﬁrst intron has been
shown to enhance PolII transcription (34). Thus, it is possible
that the non-canonical interaction of U1 snRNP at the ISPE
might affect intron splicing efﬁciency by regulating the poly-
merase II processivity or elongation rate due to the close
association between transcription and splicing (35,36). Addi-
tional experiments are necessary to clarify whether intronic
ISPE–snRNP complexes are affecting the kinetics of the
splicing reaction.
Non-canonical binding of U1 snRNA has been observed in
other gene systems with multiple effects on pre-mRNA pro-
cessing.RecruitmentofU1snRNP toapseudo 50-ss may result
in concomitant reduction of U1 snRNP binding to the proper
50-ss (37). Likewise, U1 snRNA may interfere with the poly-
adenylation signal (38–40), and targeted loading of modiﬁed
U1 snRNAs to terminal exons has proved to inhibit gene
expression (41,42). In introns, the ISPE–U1 snRNP interaction
interfering with the usage of intronic cryptic splice sites, may
be a widespread phenomenon not limited to the ATM case.
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